Batoclimab

Phase 3Monoclonal antibody

Batoclimab is one of 87 small molecule programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

Myasthenia GravisActive, not recruiting

Thyroid Eye DiseaseActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 2

Active, not recruiting

Myasthenia GravisPhase 3

Active, not recruiting

Thyroid Eye DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Myasthenia Gravis

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

7 2

Ultomiris

AstraZeneca

Phase 3

5 3

Vyvgart

Argenx

Phase 3

17 4

Cellcept

Roche

Phase 3

4 5

Soliris

AstraZeneca

Phase 3

4 6

Zilbrysq

UCB

Phase 3

4 7

Fabhalta

Johnson & Johnson

Phase 3

3 8

Arava

Sanofi

Phase 3

1 9

ENSPRYNG

Roche

Phase 3

1 10

Rhapsido

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Thyroid Eye Disease

NCT05517447

Q1 2027

Phase 2Active, not recruiting

Efficacy and Safety

NCT05581199

Phase 3Active, not recruiting

Myasthenia Gravis

NCT05403541

Clinical

Trials by Indication[1]

Thyroid Eye Disease3 trials

Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

Active, not recruiting·IImmunovant Sciences GmbH·Phase 3·NCT05517447·180 enrolled

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Active, not recruiting·IImmunovant Sciences GmbH·Phase 3·NCT05524571·100 enrolled

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Completed·IImmunovant Sciences GmbH·Phase 3·NCT05517421·114 enrolled

Myasthenia Gravis1 trial

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

Active, not recruiting·IImmunovant Sciences GmbH·Phase 3·NCT05403541·240 enrolled

Efficacy and Safety1 trial

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Active, not recruiting·IImmunovant Sciences GmbH·Phase 2·NCT05581199·277 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Enrolling by invitation·IImmunovant Sciences GmbH·Phase 2·NCT07188844·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Batoclimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Batoclimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Batoclimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immunovant Sciences GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: IImmunovant Sciences GmbH

Batoclimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Trials by Indication[1]

Thyroid Eye Disease3 trials

Myasthenia Gravis1 trial

Efficacy and Safety1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

References

Drug Info

Quick Facts

Related News